Abstract:Cancer represents the leading public health problem throughout the world. Globally, about one out of six deaths is related to cancer, which is largely due to the metastatic lesions. However, there are no effective strategies for targeting cancer metastasis. Identification of the key druggable targets maintaining metastasis is crucial for cancer treatment. In our recent study (Cai et al. (2020), Mol Cell, doi: 10.1016/j.molcel.2020.09.018), we found that activity of AMPK was enriched in metastatic tumors compared to primary tumors. Depletion of AMPK rendered cancer cells more sensitive to metabolic and oxidative stress, leading to the impairment of breast cancer lung metastasis. Activation of AMPK rewired cancer metabolism towards TCA cycle, which protects disseminated cancer cells from both metabolic and oxidative stress-induced cell death, and facilitates cancer metastasis. Further, AMPK critically maintained the activity of pyruvate dehydrogenase complex (PDH), the rate limiting enzyme involved in TCA cycle, thus favoring the pyruvate metabolism towards TCA cycle rather than converting it to lactate. Mechanistically, AMPK was shown to co-localize with PDHA, the catalytic subunit of PDH, in the mitochondrial matrix and directly triggered the phosphorylation of PDHA on Ser295 and Ser314. Hyper-phosphorylation of Ser295 and Ser314 of PDHA promotes lung metastasis through elevating activity of PDH. Of note, PDHA Ser314 phosphorylation abrogated the interaction between PDHA and PDHKs leading to the dephosphorylation on previously reported S293 site, whose phosphorylation serves as a negative signal for PDH activation, while S295 phosphorylation serves as an intrinsic catalytic site required for pyruvate metabolism. Our study presented the first evidence for the pro-metastatic property of the AMPK-PDH axis and advance our current understanding of how PDH is activated under physiological and pathological conditions.

Activation of AMPK inhibits cervical cancer growth by hyperacetylation of H3K9 through PCAF

AMPK Regulates Autophagy by Phosphorylating BECN1 at Threonine 388.

AMP‐activated Protein Kinase Regulates Cancer Cell Growth and Metabolism Via Nuclear and Mitochondria Events

AMPK maintains TCA cycle through sequential phosphorylation of PDHA to promote tumor metastasis

Acetyl-CoA Regulates Lipid Metabolism and Histone Acetylation Modification in Cancer

Loss of AMPK Activation Promotes the Invasion and Metastasis of Pancreatic Cancer Through an HSF1‐dependent Pathway

Regulation of AMPK activation by extracellular matrix stiffness in pancreatic cancer

Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function.

Involvement of AMP-activated Protein Kinase (AMPK) in Regulation of Cell Membrane Potential in a Gastric Cancer Cell Line

Targeting AMPK for cancer prevention and treatment.

Energy Stress-activated AMPK Phosphorylates Snail1 and Suppresses Its Stability and Oncogenic Function

Negative regulation of AMPKα1 by PIM2 promotes aerobic glycolysis and tumorigenesis in endometrial cancer

Histone deacetylase inhibitors inhibit cervical cancer growth through Parkin acetylation-mediated mitophagy

AMPK as a metabolic tumor suppressor: control of metabolism and cell growth

The Ras-ERK1/2 signaling pathway regulates H3K9ac through PCAF to promote the development of pancreatic cancer

PDHX acetylation facilitates tumor progression by disrupting PDC assembly and activating lactylation mediated gene expression

AMPK-HDAC5 pathway facilitates nuclear accumulation of HIF-1α and functional activation of HIF-1 by deacetylating Hsp70 in the cytosol

AMPK activation reduces cancer cell aggressiveness via inhibition of monoamine oxidase A (MAO-A) expression/activity

Phosphorylation of PDHA by AMPK Drives TCA Cycle to Promote Cancer Metastasis

Activation of AMPK Promotes Thyroid Cancer Cell Migration Through Its Interaction with PKM2 and Β-Catenin.

Acetylation regulates the nucleocytoplasmic distribution and oncogenic function of karyopherin alpha 2 in lung adenocarcinoma